Italy’s Health Ministry has legalized Bio Hemp (Bio Hemp Farming), a conglomerate, to produce cannabidiol under a distinct decree. The legalization allows Bio Hemp to use hemp-based cannabinoids in the pharmaceutical sector.
Bio Hemp Farming is a conglomerate that entails Bio Hemp Trade, a firm active in agricultural development and research that introduced a hemp industrial processing center in 2020 and Palma d’Oro Cooperative that oversees 300 hectares of Italy’s hemp plants under GACP Good Agricultural and Collection Practice protocols.
Bio Hemp is an affiliate of Crystal Hemp Group, a life science firm that creates commodities for treatment and prevention of severe inflammation with concentrations that affect the human endocannabinoid system,
The company asserted that the legalization is a move towards the generation of a licensed supply chain to acquire active ingredients for CBD-based drug substances in Italy.
Pietro Crocetta Paolo, Bio Hemp Farming’s CEO, said that after several years of work including talks with competent ministries to identify the ideal way to proceed with hemp sale for drug production from a safety and regulatory perspective, the company is proud for achieving this crucial milestone. He added that pertinent opportunities are opening up in Italy’s international market.
The organization can now create Pharma-grade cannabidiol ideal for commodities like Epidiolex-a THC-free medicine that’s rich in CBD and effective in epilepsy treatment. The medicine is permitted by United State’s FDA and the EMA .
Italy has indulged in the process of amending its regulations and laws in respect to a recent European Justice Court decision. Last year, ECJ ruled in a French court case that hemp-based cannabidiol should not be categorized as a narcotic and the compound should enjoy free trade among members of the European Union like other commodities. That verdict made the European Committee revert its earlier stand that hemp should be regarded as a narcotic among EU states.